@article{d212f452b3e042db9a95ff24e0e4037e,
title = "Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington{\textquoteright}s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 10.1038/s41591-022-01919-8)",
abstract = "In the version of this article initially published, in the first and final paragraphs of the Results section, the dosing schedule for pepinemab administration was described in error as “four times per week” instead of “every four weeks,” while in the Fig. 4b color key, the bottom, dark green key now reading “Much improved” appeared originally as “Minimally improved.” The errors have been corrected in the HTML and PDF versions of the article.",
author = "{the Huntington Study Group SIGNAL investigators} and Andrew Feigin and Evans, {Elizabeth E.} and Fisher, {Terrence L.} and Leonard, {John E.} and Smith, {Ernest S.} and Alisha Reader and Vikas Mishra and Richard Manber and Walters, {Kimberly A.} and Lisa Kowarski and David Oakes and Eric Siemers and Kieburtz, {Karl D.} and Maurice Zauderer and Elise Kayson and Jody Goldstein and Richard Barbano and Karen Marder and Praveen Dayalu and Rosas, {Herminia Diana} and Sandra Kostyk and John Kamholz and Brad Racette and Jee Bang and Daniel Claassen and Katherine McDonell and Stewart Factor and Francis Walker and Clarisse Goas and Joanne Wojcieszek and Raymond, {Lynn A.} and Jody Corey-Bloom and Victor Sung and Marissa Dean and Michael Geshwind and Alexandra Nelson and Samuel Frank and Kathrin LaFaver and Andrew Duker and Lawrence Elmer and Ali Samii and Lin, {Yi Han} and Sylvain Chouinard and Lauren Seeberger and Burton Scott and James Boyd and Nikolaus McFarland and Stimming, {Erin Furr} and Oksana Suchowersky and Claudia Testa",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2022.",
year = "2022",
doi = "10.1038/s41591-022-02070-0",
language = "English (US)",
journal = "Nature medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
}